Novartis India Limited (NSE:NOVARTIND)

Market Cap	50.04B +126.1%
Revenue (ttm)	3.71B +5.4%
Net Income	977.70M -4.9%
EPS	39.60 -4.9%
Shares Out	n/a
PE Ratio	51.19
Forward PE	n/a
Dividend	25.00 (1.24%)
Ex-Dividend Date	Jul 23, 2025

Volume	5,632
Open	2,027.40
Previous Close	2,027.40
Day's Range	2,000.00 - 2,034.80
52-Week Range	950.00 - 2,588.80
Beta	0.43
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 29, 2026

About Novartis India

Novartis India Limited is involved in the pharmaceutical business in India. The company offers therapeutic products in the areas of bone and pain under the Voveran brand; transplantation immunology under the Simulect, Certican, Sandimmun, Neoral, and Myfortic brands. It also offers neuroscience products under the Tegrital and Exelon brands. The company was incorporated in 1947 and is headquartered in Mumbai, India. As of July 29, 2026, Novartis India Limited operates as a subsidiary of Waverise Investments Limited.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1947
• Employees: 57
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: NOVARTIND

Financial Performance

In fiscal year 2026, Novartis India's revenue was 3.54 billion, a decrease of -0.54% compared to the previous year's 3.56 billion. Earnings were 931.80 million, a decrease of -7.65%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 24, 2026

Data Sources Report a data error